🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. LN-145

    Iovance Biotherapeutics B.V.

    Cervical Carcinoma

    phase 2 mab terminated

    1 trial

  2. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  3. LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  4. LN-145, ALDESLEUKIN, Lifileucel, Fludarabine 50mg Powder For Solution For Injection Or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, NIVOLUMAB, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Accord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui, IPILIMUMAB, Cyclophosphamide Injection 1 g.

    Iovance Biotherapeutics B.V.

    Neoplasm

    phase 2 small molecule active

    1 trial

  5. LX2020

    Lexeo Therapeutics

    Arrhythmogenic Cardiomyopathy

    phase 2 gene therapy active

    1 trial

  6. LX9211

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  7. LY3471851

    Nektar Therapeutics UK Limited

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    2 trials

  8. LY3471851

    Nektar Therapeutics UK Limited

    Colitis, Ulcerative

    phase 2 small molecule terminated

    1 trial

  9. LY4268989

    Eli Lilly and Company

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  10. LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa Dystrophica

    phase 2 mab completed

    1 trial

  11. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  12. Lactezin

    United Therapeutics Europe Ltd

    Hormonal Acne

    phase 2 other active

    1 trial

  13. Lanraplenib

    Lakefront Biotherapeutics NV

    Sjogren's Syndrome

    phase 2 small molecule completed

    1 trial

  14. Lanraplenib

    Lakefront Biotherapeutics NV

    Cutaneous Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  15. Lapatinib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  16. Lemborexant

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Interaction

    phase 2 small molecule completed

    1 trial

  17. Lenalidomide

    United Therapeutics Europe Ltd

    Recurrent Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  18. Lenalidomide and Gemcitabine (Dose level 11)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T-cell Lymphomas (PTCL)

    phase 2 small molecule terminated

    1 trial

  19. Lenvatinib

    United Therapeutics Europe Ltd

    Columnar Cell Variant Thyroid Gland Papillary Carcinoma

    phase 2 small molecule completed

    1 trial

  20. Lenvatinib, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 small molecule active

    1 trial

  21. Letrozole

    United Therapeutics Europe Ltd

    Lymphangioleiomyomatosis

    phase 2 small molecule completed

    1 trial

  22. Letrozole

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  23. Letybo® 50 Einheiten Pulver zur Herstellung einer Injektionslösung, Letybo 50 Einheiten Pulver zur Herstellung einer Injektionslösung

    Lacuna Pharma Pty Ltd

    Moderate and severe horizontal forehead lines.

    phase 2 small molecule active

    1 trial

  24. Leukocyte-Poor Platelet Rich Plasma (LP-PRP)

    United Therapeutics Europe Ltd

    Osteoarthritis, Knee

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources